Enjoy complimentary customisation on priority with our Enterprise License!
The sarcoma therapeutics market size is forecast to increase by USD 1.11 billion at a CAGR of 8.51% between 2023 and 2028. The market is experiencing significant growth due to several key trends and growth factors. Patient assistance programs are gaining traction as they help reduce the financial burden on patients undergoing sarcoma treatment. The research and development (R&D) of new drugs for the treatment of osteosarcoma and other types of sarcoma is another major driver for market growth. Additionally, the high treatment costs associated with sarcoma therapies are leading to increased investments in the development of more cost-effective treatment options. These factors are expected to fuel market growth and create new opportunities for market participants in the coming years.
The sarcoma drugs market is experiencing significant growth due to the increasing incidence of sarcoma, a type of cancer that affects the bones, soft tissues, fibrous tissue, cartilage, blood vessels, and other supportive tissue. According to World Health Organization (WHO), an estimated 50,000 deaths occur annually due to sarcoma, with soft tissue sarcoma accounting for approximately 85% of these cases. The developmental pipeline for sarcoma therapeutics is demand, with several novel drugs under investigation. Technological advancements in diagnostic methods, such as automated processes, are improving early detection and diagnosis, leading to increased demand for effective treatment options. The rising incidence of sarcoma, particularly in comparison to more common skin cancers, and the need for less expensive therapeutics are key factors driving market growth.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The Soft tissue sarcoma segment is estimated to witness significant growth during the forecast period. In the evolving market, a collaborative atmosphere prevails among stakeholders, fostering data sharing and public awareness to advance treatment options for this complex group of bone and soft tissue cancers. The treatment landscape encompasses various types, including checkpoint inhibitors, cancer vaccines, gene therapy, small molecules, monoclonal antibodies, and novel drugs. Hospital, retail, and online pharmacies play crucial roles in delivering these treatments to patients. Government efforts and strategic alliances support the clinical pipeline, driving label extensions and clinical trials for sarcoma. Healthcare providers prioritize manufacturing excellence and supply chain optimization to ensure patient-centric solutions. The cancer cell types, such as liposarcoma, osteosarcoma, rhabdomyosarcoma, and others, affect children and adults, necessitating grade and type-specific approaches.
Personalized medicine techniques and automated processes are integral to the development and administration of these therapies.
Get a glance at the market share of various segments Request Free Sample
The Soft tissue sarcoma segment accounted for USD 1.54 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The sarcoma drugs market is witnessing significant growth due to the increasing number of deaths caused by this rare cancer, which affects the connective tissues, including bones, muscles, tendons, blood vessels, fat, and nerves. The developmental pipeline for sarcoma treatments is robust, with pharmaceutical firms and academic organizations exploring various therapeutic modalities such as immunotherapies, targeted medicines, and combination treatments. The patient population for sarcoma is heterogeneous, with various histological subtypes, including malignant bone sarcomas and soft tissue sarcomas. Awareness initiatives and advancements in diagnostic methods are expected to increase the detection rate, leading to a larger patient base. Risk factors for sarcoma include genetic mutation, lymph system involvement, and exposure to chemicals and radiation.
The aging population also increases the risk of developing sarcoma. Current treatment modalities include chemotherapy, targeted therapy, and immuno-oncology agents. Telemedicine and remote care are emerging trends in sarcoma treatment, offering convenience and accessibility to patients. Partnerships and collaborations among stakeholders are crucial for advancing research and improving patient outcomes.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Patient assistance programs is the key driver of the market. In the collaborative atmosphere of the global market, data sharing and public awareness initiatives have gained significant traction. The treatment landscape for sarcoma, which includes bone, soft tissues, fibrous tissue, cartilage, muscle, liposarcoma, osteosarcoma, rhabdomyosarcoma, and other types, continues to evolve. Checkpoint inhibitors, cancer vaccines, gene therapy, small molecules, monoclonal antibodies, and other novel drugs are undergoing clinical trials to address the unmet medical needs of both children and adult patients. Government efforts and strategic alliances are pivotal in advancing the clinical pipeline. For instance, healthcare providers and pharmaceutical companies are partnering to offer patient-centric solutions, optimizing supply chain and manufacturing excellence.
Label extensions and clinical trial successes have led to the approval of new treatment types, such as monoclonal antibodies and targeted therapies. In this evolving market, patient-centric solutions, automation, and personalized medicine techniques are key to improving treatment outcomes. The use of checkpoint inhibitors, cancer vaccines, gene therapy, small molecules, and monoclonal antibodies continues to shape the market. Pharmacies, including hospitals, retail, and online, play a crucial role in ensuring timely and effective access to these treatments.
R and D of new drugs for OH treatment is the upcoming trend in the market. In the realm of oncology, the therapeutic landscape for sarcomas, including osteosarcoma, liposarcoma, rhabdomyosarcoma, and other bone, soft tissue, fibrous tissue, and cartilage-related cancers, is witnessing significant advancements. A collaborative atmosphere among researchers, healthcare providers, and pharmaceutical companies is driving innovation in the development of novel drugs and treatment types. Data sharing and public awareness initiatives are fostering progress in the clinical pipeline, which includes checkpoint inhibitors, cancer vaccines, gene therapy, small molecules, monoclonal antibodies, and other advanced treatment modalities. Hospital pharmacies, retail pharmacies, and online pharmacies are playing crucial roles in ensuring access to these treatments for children and adults diagnosed with various types and grades of sarcoma.
Government efforts and strategic alliances are further accelerating the development of personalized medicine techniques and clinical trials, leading to label extensions and the introduction of new drugs. Manufacturing excellence and supply chain optimization are essential components of this evolving ecosystem, ensuring the production and distribution of high-quality, patient-centric solutions. Innovations such as nanocarriers for targeted drug delivery are revolutionizing the way chemotherapeutic agents are administered, enhancing treatment efficacy while minimizing side effects. These nanocarriers can be engineered to respond to specific stimuli, enabling controlled and precise drug release. Together, these advancements are transforming the market, offering hope for improved patient outcomes.
High treatment costs is a key challenge affecting the market growth. The global market is characterized by a collaborative atmosphere among stakeholders, with data sharing and public awareness initiatives playing a crucial role in driving market growth. The treatment landscape for sarcoma, which includes bone, soft tissues, fibrous tissue, cartilage, muscle, liposarcoma, osteosarcoma, rhabdomyosarcoma, and other types, is diverse, with various treatment types such as checkpoint inhibitors, cancer vaccines, gene therapy, small molecules, monoclonal antibodies, and novel drugs under development in the clinical pipeline. Strategic alliances between healthcare providers, government efforts, and pharmaceutical companies are fostering innovation and advancing label extensions for existing drugs. Manufacturing excellence and supply chain optimization are essential for ensuring the availability of these complex therapeutics in hospital pharmacies, retail pharmacies, and online pharmacies.
Personalized medicine techniques, such as precision oncology, are also gaining traction in the market, offering patient-centric solutions for this challenging disease. Despite the high cost of sarcoma therapeutics, which is attributed to the complex manufacturing process and high R&D costs, efforts are being made to increase patient access through reimbursement policies, patient assistance programs, and affordable pricing strategies.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Adaptimmune Therapeutics plc - The company provides a range of sarcoma therapeutics solutions, branded as Tibsovo, to cater to the medical needs of patients diagnosed with this condition.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The sarcoma drugs market is experiencing significant growth due to the increasing number of deaths caused by this rare cancer, which affects the connective tissues such as bones, muscles, tendons, blood vessels, fat, nerves, and skin. The heterogeneous group of sarcoma tumors includes subtypes like malignant bone sarcomas, soft tissue sarcomas, and others. The developmental pipeline is rich with therapeutic modalities, including immunotherapies, targeted medicines, and combination treatments. Pharmaceutical firms and academic organizations are collaborating to advance research and improve diagnostic methods for early detection and accurate diagnosis. The patient population for sarcoma is relatively small, but the risk factors, including genetic mutation, chemical exposure, radiation, and age groups, necessitate the development of effective treatments.
The use of telemedicine and remote care is also gaining traction in the management of sarcoma, expanding access to care for patients in remote areas. The market is expected to grow at a steady pace due to the increasing awareness of sarcoma and the ongoing efforts to develop new therapeutic agents and combination treatments.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
143 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 8.51% |
|
Market growth 2024-2028 |
USD 1.11 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
7.67 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 41% |
|
Key countries |
US, China, Germany, Canada, and UK |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Adaptimmune Therapeutics plc, Advenchen Laboratories LLC, Agenus Inc., Agios Inc., Athenex Inc., Bayer AG, Bristol Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Ipsen Pharma, Johnson and Johnson Services Inc., Karyopharm Therapeutics Inc., LadRx Corp., Mirati Therapeutics Inc., Novartis AG, Pfizer Inc., PharmaMar SA, and SillaJen Co. Ltd. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.